Why a blend has one dose, not several
Say a vial holds 5 mg of CJC-1295 and 5 mg of ipamorelin. If you draw enough for 100 mcg of CJC-1295, you get 100 mcg of ipamorelin too, even though ipamorelin is usually cited at 200 to 300 mcg. Drawing more to reach the ipamorelin figure doubles or triples the CJC-1295.
So each blend below is dosed against one component, called the anchor, and the others follow. If you want to control each peptide on its own, separate vials are the only way to do it.
13 blends
A highlighted note means one vial cannot give every component its usual dose at the same time.
Also sold as Wolverine
Dose anchored to BPC-157
5 mg + 5 mg (10 mg total)10 mg + 10 mg (20 mg total)30 mg + 30 mg (60 mg total)5 mg BPC + 10 mg TB (15 mg total, compounding pharmacy)
Community protocols describe 500 to 1000 mcg of total blend per day, which on a 1:1 vial is 250 to 500 mcg of each peptide. Dosing at the top of that range puts TB-500 at about 3.5 mg per week, inside its own commonly cited 2 to 5 mg weekly range. Dosing at the bottom puts TB-500 at about 1.75 mg per week, under its own floor. A daily blend also spreads TB-500 across seven small doses, where it is usually given two or three times a week on its own.
CagriSemaInvestigational
Also sold as cagrilintide and semaglutide
Dose anchored to Semaglutide
5 mg + 5 mg (10 mg total)10 mg + 10 mg (20 mg total)2.4 mg + 2.4 mg (4.8 mg total, the trial dose)
The ratio is fixed at 1:1, so a draw giving 2.4 mg of semaglutide gives 2.4 mg of cagrilintide with it. That is the pairing REDEFINE 1 tested, and it is the one case in this library where a blend's ratio comes from a trial protocol rather than from whoever filled the vial.
Also sold as CJC-1295 + GHRP-2
Dose anchored to CJC-1295 (no DAC)
2 mg + 2 mg (4 mg total)
CJC-1295 (no DAC) is usually cited at about 100 mcg and GHRP-2 at 100 to 300 mcg. One draw from a 1:1 vial at the CJC-1295 dose delivers 100 mcg of GHRP-2, the bottom of its own range. Drawing enough to reach the top of the GHRP-2 range triples the CJC-1295.
Also sold as Coremend
Dose anchored to BPC-157
25 + 10 + 10 mg (45 mg total)10 + 10 + 10 mg (30 mg total)
On the 25/10/10 vial, a draw giving 500 mcg of BPC-157 gives 500 mcg of KPV and 1.25 mg of TB-500 alongside it. Daily dosing at that rate puts TB-500 near 8.75 mg per week, well above its own commonly cited 2 to 5 mg weekly range, and delivers it daily where it is usually given two or three times a week. The uneven ratio is the reason this blend behaves differently from the 1:1 Wolverine vial. On the even 10/10/10 vial the same draw gives 500 mcg each of TB-500 and KPV, which puts TB-500 near 3.5 mg per week, inside its commonly cited range.
Also sold as GLOW
Dose anchored to BPC-157
50 + 10 + 10 mg (70 mg total, most common)70 + 10 + 10 mg (90 mg total)5 + 2.5 + 2.5 mg (10 mg total)
A commonly described GLOW protocol is 10 units from a 70 mg vial mixed in 2 mL, which delivers 2.5 mg GHK-Cu, 500 mcg BPC-157, and 500 mcg TB-500 in one draw. That puts BPC-157 at the top of its own range and TB-500 at about 3.5 mg per week, inside its own. GHK-Cu has no established injected dose to compare against.
Also sold as CJC/Ipa
Dose anchored to CJC-1295 (no DAC)
5 mg + 5 mg (10 mg total)6 mg + 6 mg (12 mg total)
The two commonly cited standalone doses cannot both be met from a 1:1 vial. CJC-1295 is usually given at about 100 mcg and ipamorelin at 200 to 300 mcg, but one draw from a 5 mg and 5 mg vial delivers the same amount of each. Anchoring to CJC-1295 leaves ipamorelin under its usual range; anchoring to ipamorelin puts CJC-1295 two to three times over its own. This is a real limit of the product, not something a calculator can solve.
Also sold as KLOW
Dose anchored to BPC-157
50 + 10 + 10 + 10 mg (80 mg total, most common)
KLOW is GLOW with 10 mg of KPV added, so the same draw that gives 500 mcg of BPC-157 also gives 500 mcg of KPV. That sits inside KPV's own commonly cited 0.2 to 0.5 mg daily range. GHK-Cu has no established injected dose to compare against.
Also sold as MitoPrime
Dose anchored to MOTS-c
100 + 10 + 10 mg (120 mg total)
The ratio is locked, so the whole vial is one dose decision. Taking MOTS-c across its commonly cited 5 to 10 mg weekly range also delivers 50 to 100 mg of NAD+, which sits inside NAD+'s own usual range. The same draw delivers 5 to 10 mg of 5-Amino-1MQ, at or above the top of the range people use when injecting it on its own. Nothing in this vial is being under-delivered, and the 5-Amino-1MQ portion is the one to watch.
Also sold as Regeno
Dose anchored to BPC-157
10 + 10 + 10 mg (30 mg total)
On the even 10/10/10 vial, a draw giving 500 mcg of BPC-157 gives 500 mcg each of TB-500 and Cartalax alongside it. Daily dosing at that rate puts TB-500 near 3.5 mg per week, inside its own commonly cited 2 to 5 mg weekly range, though spread across seven small doses where it is usually given two or three times a week. The even ratio is what makes this blend easier to reason about than Coremend.
Also sold as Retatrutide + Cagrilintide
No dose for the blend
10 mg + 10 mg (20 mg total)
A 1:1 vial couples every retatrutide titration step to an identical cagrilintide step. Retatrutide is titrated slowly because its gastrointestinal side effects are dose-limiting, and cagrilintide has its own nausea profile. In one vial the two cannot be adjusted separately, which removes the main tool for managing either.
Also sold as Selank + Semax
No dose for the blend
10 mg + 10 mg (20 mg total)30 mg + 30 mg (60 mg total)
At a 1:1 ratio one draw delivers equal milligrams of both. That is a decision about the vial rather than about the two peptides, which have different potencies and were never matched to each other in any study.
Also sold as Serm/Ipa
Dose anchored to Sermorelin
18 mg sermorelin + 15 mg ipamorelin (33 mg total)9 mg sermorelin + 15 mg ipamorelin (24 mg total)9 mg + 9 mg (18 mg total)5 mg + 5 mg (10 mg total)
On a 9 mg and 9 mg vial, the low end of sermorelin's range puts ipamorelin at 200 mcg, inside its own. The high end puts ipamorelin at 500 mcg, about 1.7 times its usual top. The uneven vials sold as 18/15 and 9/15 shift this further, which is why the milligram figure on your own label matters more than the shorthand.
Also sold as Tesa/Ipa
Dose anchored to Tesamorelin
10 mg tesamorelin + 3 mg ipamorelin (13 mg total)5 mg + 5 mg (10 mg total)
Tesamorelin's approved daily dose is between 1.28 and 2 mg depending on which of the three products you compare against. Reaching 2 mg from a 10 mg and 3 mg vial also delivers 600 mcg of ipamorelin, about twice its commonly cited 200 to 300 mcg. From a 5 mg and 5 mg vial it delivers 2 mg of ipamorelin, closer to seven times that. The ratio you happen to buy changes the ipamorelin dose by more than three-fold.